Novel insights for the treatment of Alzheimer's disease

Adlard, 2008, Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hdroxy quinoline analogs is associated with decreased interstitial Abeta, Neuron, 59, 43, 10.1016/j.neuron.2008.06.018 Aisen, 2008, Alzhemed: a potential treatment for Alzheimer's disease, Curr Alzheimer Res, 4, 473, 10.2174/156720507781788882 Alvarez, 2006, A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolsysin in patients with mild to moderate Alzheimer's disease, Eur J Neurol, 13, 43, 10.1111/j.1468-1331.2006.01222.x Arendt, 2009, Synaptic degeneration in Alzheimer's disease, Acta Neuropathol, 118, 167, 10.1007/s00401-009-0536-x Bachurin, 2003, Mitochondria as a targe for neurotoxins and neuroprotective agents, Ann NY Acad Sci, 993, 334, 10.1111/j.1749-6632.2003.tb07541.x Bar-Am, 2009, The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats, J Mol Neurosci, 37, 135, 10.1007/s12031-008-9139-6 Bartus, 1982, The cholinergic hpothesis of geriatric memory dysfunction, Science, 217, 408, 10.1126/science.7046051 Baum, 2008, Six-month randomized, placebo-conrolled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease, J Clin Pharmacol, 28, 110 Bishop, 2008, Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons, Exp Neurol, 211, 574, 10.1016/j.expneurol.2008.03.004 Bolognesi, 2009, Alzheimer's disease: new approaches to drug discovery, Curr Opin Chem Biol, 13, 303, 10.1016/j.cbpa.2009.04.619 Buckingham, 2009, Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection, Pharmacol Rev, 61, 39, 10.1124/pr.108.000562 Bush, 2003, The metallobiology of Alzheimer's disease, Trends Neurosci, 26, 207, 10.1016/S0166-2236(03)00067-5 Caccamo, 2007, Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles, Am J Pathol, 170, 1669, 10.2353/ajpath.2007.061178 Castellani, 2006, Neuropathology of Alzheimer disease: pathognomonic but not pathogenic, Acta Neuropathol, 111, 503, 10.1007/s00401-006-0071-y Chaturvedi, 2008, Mitochondrial approaches for neuroprotection, Ann NY Acad Sci, 1147, 395, 10.1196/annals.1427.027 Chen, 1998, Delivery of nerve growth factor to the brain via the olfactory pathway, J Alzheimers Dis, 1, 35, 10.3233/JAD-1998-1102 Cummings, 2007, Disease-modifying therapies for Alzheimer's disease. Challenges to early intervention, Neurology, 69, 1622, 10.1212/01.wnl.0000295996.54210.69 Cummings, 2008, Integrating symptomatic and disease-modifying treatments, CNS Spectr, 13, 28, 10.1017/S1092852900027024 Cummings, 2009, Defining and labeling disease-modifying treatments for Alzheimer's disease, Alzheimers Dement, 5, 406, 10.1016/j.jalz.2008.12.003 De Felice, 2008, Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Abeta oligomers, Neurobiol Aging, 29, 1334, 10.1016/j.neurobiolaging.2007.02.029 De la Monte, 2009, Insulin resistance and Alzheimer's disease, BMB Rep, 42, 475, 10.5483/BMBRep.2009.42.8.475 Deane, 2009, Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease, CNS Neurol Dis Drug Targets, 8, 16, 10.2174/187152709787601867 Desire, 2008, EHT-0202: a neuroprotective and procognitive alpha-secretase stimulator targeted towards Alzheimer disease therapy, Alzheimers Dement, 4, T168, 10.1016/j.jalz.2008.05.442 Doody, 2008, We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer's disease drug development, Alzheimers Dement, 4, S21, 10.1016/j.jalz.2007.10.010 Doody, 2008, Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study, Lancet, 372, 207, 10.1016/S0140-6736(08)61074-0 Douillet, 2009, What have we learned from the xaliproden Sanofi-Aventis trials, J Nutr Health Aging, 13, 365, 10.1007/s12603-009-0045-6 Dubois, 2007, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria, Lancet Neurol, 6, 734, 10.1016/S1474-4422(07)70178-3 Dunbar, 2007, Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI), J Psychopharmacol, 21, 171, 10.1177/0269881107066855 Duyckaerts, 1997, Prevalence, incidence and duration of Braak's stages in the general population: can we know?, Neurobiol Aging, 18, 362, 10.1016/S0197-4580(97)00047-X Ebenshade, 2008, The histamine H3 receptor: an attractive target fr the treatment of cognitive disorders, Br J Pharmacol, 154, 1166, 10.1038/bjp.2008.147 Eikelenboom, 2006, The significance of neuroinflammation in understanding Alzheimer's disease, J Neural Transm, 113, 1685, 10.1007/s00702-006-0575-6 Eriksdotter-Jönhagen, 1998, Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease, Dement Geriatr Cogn Disord, 9, 246, 10.1159/000017069 Eriksen, 2003, NSAIDs and enatniomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo, J Clin Invest, 112, 440, 10.1172/JCI18162 Farlow, 2008, Treatment options in Alzheimer's disease: maximizing benefit, managing expectations, Dement Geriatr Cogn Disord, 25, 408, 10.1159/000122962 Gabuzda, 1994, Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative, J Biol Chem, 269, 13623, 10.1016/S0021-9258(17)36875-8 Gauthier, 2009, Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study, J Nutr Health Aging, 13, 550, 10.1007/s12603-009-0106-x Giannakopoulos, 2009, Pathological substrates of cognitive decline in Alzheimer's disease, Front Neurol Neurosci, 24, 20, 10.1159/000197881 Gibson, 2010, Cause and consequence: Mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative disease, Biochim Biophys Acta, 1802, 122, 10.1016/j.bbadis.2009.08.010 Golde, 2006, Disease modifying therapy for AD?, J Neurochem, 99, 689, 10.1111/j.1471-4159.2006.04211.x Greco, 2009, Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells, Biochem Biophys Res Commun, 380, 98, 10.1016/j.bbrc.2009.01.041 Green, 2009, Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer's disease: a randomized controlled trial, JAMA., 302, 2557, 10.1001/jama.2009.1866 Greenamyre, 1988, Glutamate transmission and toicity in Alzheimer's disease, Prog Neuro-Psych Biol Psych., 12, 421, 10.1016/0278-5846(88)90102-9 Grimmer, 2006, Effects of cholinesterase inhibitors on behavioural disturbances in Alzheimer's disease. A systematic review, Drugs Aging, 23, 957, 10.2165/00002512-200623120-00003 Grundman, 2003, A multicenter, randomized, placebo controlled, multiple-dose, safety and pahrmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients, Life Sci, 73, 539, 10.1016/S0024-3205(03)00320-5 Gustafson, 2006, Adiposity indices and dementia, Lancet Neurol, 5, 713, 10.1016/S1474-4422(06)70526-9 Hampel, 2009, Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study, J Clin Psychiatry, 70, 922, 10.4088/JCP.08m04606 Hanger, 2009, Tau phosphorylation: the therapeutic challenge for neurodegenerative disease, Trends Mol Med, 15, 112, 10.1016/j.molmed.2009.01.003 Hardy, 2009, The amyloid hypothesis for Alzheimer's disease: a critical reappraisal, J Neurochem, 110, 1129, 10.1111/j.1471-4159.2009.06181.x Hawkes, 2010, Small molecule beta-amyloid inhibitors that stabilize protofibrillar structures in vitor improve cognition and pathology in a mouse model of Alzheimer's disease, Eur J Neurosci, 31, 203, 10.1111/j.1460-9568.2009.07052.x Henley, 2009, Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease, Expert Opin Pharmacother, 10, 1657, 10.1517/14656560903044982 Hind, 2008, Efficacy and tolerability of SB-742457, a novel 5HT6 receptor antagonis, in subjects with mild-to-moderate Alzheimer's disease (AD), Alzheimers Dement, 4, T166, 10.1016/j.jalz.2008.05.437 Holmes, 2008, Long-term effects of A beta 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial, Lancet, 372, 216, 10.1016/S0140-6736(08)61075-2 Hooper, 2008, The GSK3 hypothesis of Alzheimer's disease, J Neurochem, 104, 1433, 10.1111/j.1471-4159.2007.05194.x Jakob-Roetne, 2009, Alzheimer's disease: From pathology to therapeutic approaches, Angew Chem Int Ed, 48, 3030, 10.1002/anie.200802808 Kamphuis, 2009, Nutrition and Alzheimer's disease: pre-clinical concepts, Eur J Neurol, 16, 12, 10.1111/j.1468-1331.2009.02737.x Kandiah, 2009, Therapeutic potential of statins in Alzheimer's disease, J Neurol Sci, 283, 230, 10.1016/j.jns.2009.02.352 Kihara, 1998, Stimulation of alpha-4-beta-2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity, Brain Res, 792, 331, 10.1016/S0006-8993(98)00138-3 Lannfelt, 2008, Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial, Lancet Neurol, 7, 779, 10.1016/S1474-4422(08)70167-4 Lieb, 2009, Association of plasma leptin levels with incident Alzheimer's disease and MRI measures of brain aging, JAMA, 302, 2565, 10.1001/jama.2009.1836 Lyketsos, 2007, Naproxen and celecoxib do no prevent AD in early results from a randomized controlled trial, Neurology, 68, 1800, 10.1212/01.wnl.0000260269.93245.d2 Maelicke, 2000, Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease, Dement Geriatr Cogn Disord, 11, 11, 10.1159/000051227 Marksteiner, 2004, Treatment strategies in Alzheimer's disease with a focus on early pharmacological interventions, Drugs Aging, 21, 415, 10.2165/00002512-200421070-00001 Martin, 2009, Inhibition of glycogen synthase kinase-3beta downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A, Brain Res, 1252, 66, 10.1016/j.brainres.2008.11.057 Matsuoka, 2008, A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease, J Pharmacol Exp Ther, 325, 146, 10.1124/jpet.107.130526 Mitchell, 2005, 5-HT6 receptors: a novel target for cognitive enhancement, Pharmacol Ther, 108, 320, 10.1016/j.pharmthera.2005.05.001 Mohs, 2000, Longitudinal studies of cognitive, functionsl and behavioural change in patients with Alz heimer's disease, Stat Med, 19, 1401, 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1401::AID-SIM432>3.0.CO;2-X Nagahara, 2008, Neuroprotecive effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease, Nat Med, 15, 331, 10.1038/nm.1912 Nicoll, 2003, Neuropathology of human Alzheimer disease after immunization with amylodi-beta peptide: a case report, Nat Med, 9, 448, 10.1038/nm840 Nimmrich, 2009, Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric beta-amyloid, Rev Neurosci, 20, 1, 10.1515/REVNEURO.2009.20.1.1 Orgogozo, 2003, Subacute meningoencephalitis in a subset of patients with AD after a beta 42 immunization, Neurology, 61, 46, 10.1212/01.WNL.0000073623.84147.A8 Peleshok, 2006, Functional mimetics of neurotrophins and their receptors, Biochim Soc Trans, 12, 1015 Plosker, 2009, A review of its use in dementia, Drugs Aging, 26, 893, 10.2165/11203320-000000000-00000 Price, 2007, Advances in small molecules promoting neurotrophic function, Pharmacol Ther, 115, 292, 10.1016/j.pharmthera.2007.03.005 Querfurth, 2010, Alzheimer's disease, N Engl J Med, 362, 329, 10.1056/NEJMra0909142 Rabiner, 2009, Effects of 12months of treatment with the PPARgamma agonist rosiglitazone on brain glucose metabolism in Alzheimer's disease: A 18F-FDG PET study, Alzheimers Dement, 5, P207, 10.1016/j.jalz.2009.04.117 Raschetti, 2007, Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials, PLoS Med, 4, 1818, 10.1371/journal.pmed.0040338 Reynolds, 2008, Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases, J Biol Chem, 283, 18177, 10.1074/jbc.M709715200 Ringman, 2005, A potential role of the curry spice curcumin in Alzheimer's disease, Curr Alzheimer Res, 2, 131, 10.2174/1567205053585882 Risner, 2006, Efficacy of rosiglitazone in a genetically defined population with mild-to moderate Alzheimer's disease, Pharmacogenomics J, 6, 246, 10.1038/sj.tpj.6500369 Ritchie, 2003, Metal-protein attenuation with iodochorhydroxyquin (Clioquinol) targeting A beta amyloid deposition and toxicity in Alzheimer disease. A pilot phase 2 clinical trial, Arch Neurol, 60, 1685, 10.1001/archneur.60.12.1685 Sabbagh, 2009, Drug development for Alzheimer's disease: where are we now and where are we headed?, Am J Geriatr Pharmacol, 7, 167, 10.1016/j.amjopharm.2009.06.003 Sabbagh, 2010, Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea, Curr Opin Invest Drugs, 11, 80 Salloway, 2009, A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease, Neurology, 73, 2061, 10.1212/WNL.0b013e3181c67808 Scheltens, 2010, Efficacy of a medical food in mild Alzheimer's disease: a randomized, controlled trial, Alzheimers Dement, 6, 1, 10.1016/j.jalz.2009.10.003 Schliebs, 2006, The significance of the cholinergic system in the brain during aging and in Alzheimer's disase, J Neural Transm, 113, 1625, 10.1007/s00702-006-0579-2 Selenica, 2007, Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation, Br J Pharmacol, 152, 959, 10.1038/sj.bjp.0707471 Sergeant, 2008, Biochemistry of Tau in Alzheimer's disease and related neurological disorders, Expert Rev Proteomics, 5, 207, 10.1586/14789450.5.2.207 Sigurdsson, 2008, Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies, J Alzheimers Dis, 15, 157, 10.3233/JAD-2008-15202 Smith, 2008, Mitochondria-targeted antioxidants in the treatment of disease, Ann NY Acad Sci, 1147, 105, 10.1196/annals.1427.003 Soto, 1998, Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy, Nature Med, 4, 822, 10.1038/nm0798-822 Spires-Jones, 2009, Tau pathophysiology in neurodegeneration: a tangled issue, Trends Neurosci, 32, 150, 10.1016/j.tins.2008.11.007 Srikanth, 2009, Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease, Neurobiol Aging Sultana, 2009, Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis, Acta Neuropathol, 118, 131, 10.1007/s00401-009-0517-0 Swerdlow, 2007, Pathogenesis of Alzheimer's disease, Clin Interv Aging, 2, 347 Swerdlow, 2009, The Alzheimer's disease mitochondrial cascade hypothesis: an update, Exp Neurol, 218, 308, 10.1016/j.expneurol.2009.01.011 Tamagno, 2008, Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein, J Neurochem, 104, 683 Tapia-Arancibia, 2008, New insights into brain BDFN function in normal aging and alzheimer disease, Brain Res Rev, 59, 201, 10.1016/j.brainresrev.2008.07.007 Tezapsidis, 2009, Leptin: a novel therapeutic strategy for Alzheimer's disease, J Alzheimers Dis, 16, 731, 10.3233/JAD-2009-1021 Thomsen, 2010, Cognitive improvement by activation of alpha 7 nicotinic acetylcholine receptors: from animal models to human pathophysiology, Curr Pharm Des, 16, 323, 10.2174/138161210790170094 Tuszynski, 2005, A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease, Nat Med, 11, 551, 10.1038/nm1239 Uttara, 2009, Oxidative stress and neurodegenerative disease: a review of upstream and downstream antioxidant therapeutic options, Curr Neuropharmacol, 7, 65, 10.2174/157015909787602823 Waters, 1988, Cognitive enhancing agents: current status in the treatment of Alzheimer's disease, Can J Neurol Sci, 15, 249, 10.1017/S0317167100027694 Webster, 2008, Small molecule activators of the Trk receptors for neuroprotection, BMC Neurosci, 9, S1, 10.1186/1471-2202-9-S2-S1 Wei, 2007, Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease, J Neural Transm, 114, 629, 10.1007/s00702-007-0630-y Weinshenker, 2008, Functional consequences of locus coeruleus degeneration in Alzheimer's disease, Curr Alzheimer Res, 5, 342, 10.2174/156720508784533286 Weller, 2009, Microvasculature changes and cerebrl amyloid angiopathy in Alzheimer's disease and their potential impact on therapy, Acta Neuropathol, 118, 87, 10.1007/s00401-009-0498-z Wilcock, 2008, Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial, Lancet Neurol, 7, 483, 10.1016/S1474-4422(08)70090-5 Willem, 2006, Control of peripheral nerve myelination by the beta-secretase BACE1, Science, 314, 664, 10.1126/science.1132341 Wischik, 2008, Taui aggregation inhibitor (TAI) therapy with Rember TM arrests disease progression in mild and moderate Alzheimer's disease over 50weeks, Alzheimers Dement, 4, T167, 10.1016/j.jalz.2008.05.438 Wisniewski, 2008, Amyloid-beta immunisation for Alzheimer's disease, Lancet Neurol, 7, 805, 10.1016/S1474-4422(08)70170-4 Wisniewski, 2008, Preventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors, BMD Neuroscience, 9, S5, 10.1186/1471-2202-9-S2-S5 Zhang, 2005, Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model, Proc Natl Acad Sci USA, 102, 227, 10.1073/pnas.0406361102 Zhu, 2006, Economic considerations in the management of Alzheimer's disease, Clin Interv Aging, 1, 143, 10.2147/ciia.2006.1.2.143 Zuccato, 2009, Brain-derived neuroptrophic factor in neurodegenerative disease, Nat Rev Neurol, 5, 311, 10.1038/nrneurol.2009.54